logo-loader
viewArix Bioscience PLC

Arix Bioscience flags “signs of efficacy” at Aura eye cancer trial

“If approved, AU-011 represents the first potential new treatment for choroidal melanoma in several decades”

Arix Bioscience PLC - Arix Bioscience’s Aura Biosciences says candidate shows “early signs of efficacy”
The data showed that multiple administrations of AU-011 to 46 patients were “well-tolerated”

Biotech companies backer Arix Bioscience PLC (LON:ARIX) has reported the lead candidate of its portfolio company Aura Biosciences shows “early signs of efficacy”.

The firm is currently evaluating the safety and efficacy of AU-011, which is an injection to treat eye cancer, in the clinical trial phase 1b/2.

READ: Jefferies puts 229p target on Arix Bioscience

The data showed that multiple administrations of AU-011 to 46 patients were “well-tolerated” and caused adverse effects that were manageable with standard treatments.

Only one patient experienced vision loss, considered a severe adverse effect.

Treatment resulted in tumour control in 15 of the 17 patients who had tumour growth before enrolling in the trial, which is a 88% success rate.

“AU-011 is administered via a simple, two-step procedure which includes an intravitreal injection followed by a laser application; all of which is completed in the physician’s office,” said Jay S Duker, advisor at Aura. 

“If approved, AU-011 represents the first potential new treatment for choroidal melanoma in several decades.”

Quick facts: Arix Bioscience PLC

Price: 114.5 GBX

LSE:ARIX
Market: LSE
Market Cap: £155.21 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Arix Bioscience PLC named herein, including the promotion by the Company of Arix Bioscience PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Arix Bioscience acquires stake in novel firm developing sickle cell treatment

Arix Bioscience PLC (LON:ARIX) investment associate John Cassidy talks Proactive London through its decision to invest US$15mln (£11.3mln) in Imara - a firm which is developing treatments for sickle cell disease. Through the deal Arix receives a 10% stake in the company while also...

on 19/3/19

2 min read